A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: Continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist

Cancer

Volumn 94, Issue 9, 2002, Pages 2333-2343

  Abraham, Jame ^a   Bakke, Susan ^a   Rutt, Ann ^a   Meadows, Beverly ^a   Merino, Maria ^a   Alexander, Richard ^a   Schrump, David ^a   Bartlett, David ^a   Choyke, Peter ^b   Robey, Rob ^a   Hung, Elizabeth ^a   Steinberg, Seth M ^a   Bates, Susan ^a   Fojo, Tito ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Adrenocortical carcinoma (ACC); Combination chemotherapy; Doxorubicin; Drug resistance reversal; Etoposide; Mitotane; P glycoprotein (Pgp); Vincristine

Indexed keywords

AMINOGLUTETHIMIDE; CARBOPLATIN; CISPLATIN; CORTICOTROPIN; DEXAMETHASONE; DIPHENHYDRAMINE; DOXORUBICIN; DROPERIDOL; ETOPOSIDE; FLUDROCORTISONE; GLYCOPROTEIN P; GLYCOPROTEIN P ANTAGONIST; HYDROCORTISONE; LORAZEPAM; METOCLOPRAMIDE; MITOTANE; ONDANSETRON; PACLITAXEL; PHENOTHIAZINE DERIVATIVE; PROTEIN INHIBITOR; RHODAMINE; UNCLASSIFIED DRUG; VALSPODAR; VINBLASTINE; VINCRISTINE;

ADRENAL CORTEX CARCINOMA; ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; DIARRHEA; FATIGUE; FEMALE; HUMAN; MALE; MENTAL DISEASE; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL CARCINOMA; ADULT; AGED; ANTIGENS, CD56; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DOXORUBICIN; ETOPOSIDE; FEMALE; HUMANS; MALE; MIDDLE AGED; MITOTANE; NEOPLASM METASTASIS; P-GLYCOPROTEIN; RHODAMINES; SURVIVAL RATE; TREATMENT OUTCOME; VINCRISTINE;

EID: 0036569569     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.10487     Document Type: Article

References (35)

1. Adrenocortical carcinoma
2. Adrenal cortical carcinoma. Epidemiology and treatment with mitotane and a review of the literature
3. Functioning and nonfunctioning adrenocortical carcinoma: Clinical presentation and therapeutic strategies
4. Adrenal tumors
5. An eleven-year experience with adrenocortical carcinoma
6. Chemotherapy of adrenocortical cancer with o'p'DDD
7. Adrenal cortical carcinoma. Results of treatment with o,p'DDD in 138 patients
8. Mitotane use in inoperable adrenalcortical carcinoma
9. Adrenal cortical carcinoma. A study of 77 cases
10. The treatment of adrenocortical carcinoma with o,p'-DDD: Prognostic implications of serum level monitoring
11. Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer
12. Adrenal cortical carcinoma
13. Eastern Cooperative Oncology Group study 1879: Mitotane and adriamycin in patients with advanced adrenocortical carcinoma
14. Cytotoxic chemotherapy in adrenal cortical carcinoma
15. Multidrug resistance
16. P-glycoprotein expression and multidrug resistance in adrenocortical carcinoma
17. Expression of P-glycoprotein in relation to clinical manifestation, treatment and prognosis of adrenocortical cancer
18. Mitotane enhances cytotoxicity of chemotherapy in cell lines expressing a multidrug resistance gene (mdr-1/P-glycoprotein) which is also expressed by adrenocortical carcinomas
19. A patient with adrenocortical carcinoma: Characterization of its biological activity and drug resistance profile
20. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy
21. Efflux of rhodamine from CD56+ cells as a surrogate marker for reversal of P-glycoprotein-mediated drug efflux by PSC 833
22. Analysis and interpretation of the comparison of survival by treatment outcome variables in cancer clinical trials
23. Adrenocortical carcinoma in surgically treated patients: A retrospective study on 156 cases by the French Association of Endocrine Surgery
24. Recurrent or metastatic disease in select patients with adrenocortical carcinoma. Aggressive resection vs chemotherapy
25. Role of reoperation in recurrence of adrenal cortical carcinoma: Results from 188 cases collected in the Italian National Registry for Adrenal Cortical Carcinoma
26. I Metabolic activation and binding of mitotane in adrenal cortex homogenates
27. Optimal treatment of adrenocortical carcinoma with mitotane: Results in a consecutive series of 96 patients
28. O,p'-DDD (mitotane) levels in plasma and tissues during chemotherapy and at autopsy
29. Phase II trial of mitotane and cisplatin in patients with adrenal carcinoma: A Southwest Oncology Group study
30. Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma: A Southwest Oncology Group Study
31. Multidrug resistance in human tumors
32. Phase I trial of XR9576 in healthy volunteers demonstrates modulation of P-glycoprotein in CD56+ lymphocytes after oral and intravenous administration
33. Selectivity of the multidrug resistance modulator, LY335979, for P-glycoprotein and effect on cytochrome P-450 activities
34. The orally administered P-glycoprotein inhibitor R101933 does not alter the plasma pharmacokinetics of docetaxel
35. Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance